AndraValvulotome™

Now Available from LeMaitre

Product Information

The AndraValvulotome demonstrates a technical success rate of 96.6% and a primary patency rate of 89.9% at 30-day follow-up.¹

AndraValvulotome Features

• Automatic self-sizing and self-centering technology through its basket geometry and material
• The automatic adjustment to the vein diameter ensures cutting of various valves
• Atraumatic tip
• The OTW-system must be used with a guidewire

PMCF Study
Models & Specs

Learn more about the AndraValvulotome in the PMCF Study.

“The multicenter, post-market observational study conducted in 2021 in 11 German Centers did demonstrate the technical success rate in 96.6% and the primary patency rate of 89.9% at 30 days follow-up. The clinical efficacy was rated as very good in 81% of the patients. Conclusion: The AndraValvulotome™ can be considered a safe and effective device to disrupt venous valves during in situ non-reversed bypass surgeries using GSV grafts in patients with PAD.”¹

(1) Souri Y et al. (2023) Valvulotomy of the great saphenous vein in ex situ non‑reversed and in situ setting: a multicenter post‑market study to assess the safety and efficacy of the AndraValvulotome™. Heidelberg: Langenbeck’s Archives of Surgery. Springer Nature: 448 - 449 (https://doi.org/10.1007/s00423-023-03189-5)